December 2002
Volume 43, Issue 13
Free
ARVO Annual Meeting Abstract  |   December 2002
Systemic Carbenoxolone Reduces Intraocular Pressure in Patients with Ocular Hypertension
Author Affiliations & Notes
  • CM G Cheung
    Ophthalmology Division of Immunity and Infection
    University of Birmingham Birmingham United Kingdom
  • S Rauz
    Ophthalmology Division of Immunity and Infection
    University of Birmingham Birmingham United Kingdom
  • PI Murray
    Ophthalmology Division of Immunity and Infection
    University of Birmingham Birmingham United Kingdom
  • PM Stewart
    Endocrinology Division of Medical Sciences
    University of Birmingham Birmingham United Kingdom
  • Footnotes
    Commercial Relationships   C.M.G. Cheung, None; S. Rauz, None; P.I. Murray, None; P.M. Stewart, None. Grant Identification: Medical Research Council, UK; Research in Eye Disease Trust, UK.
Investigative Ophthalmology & Visual Science December 2002, Vol.43, 4079. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      CM G Cheung, S Rauz, PI Murray, PM Stewart; Systemic Carbenoxolone Reduces Intraocular Pressure in Patients with Ocular Hypertension . Invest. Ophthalmol. Vis. Sci. 2002;43(13):4079.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: Our recent studies have localised 11 beta-hydroxysteroid dehydrogenase type 1 (11ß-HSD1), an isozyme which activates cortisol from cortisone, to the human ocular non-pigmented ciliary epithelium, and in an open blinded study conducted on healthy male volunteers, systemic inhibition of this isozyme with oral carbenoxolone (CBX) resulted in a 17% reduction of intraocular pressure (IOP). The aim of this study was to evaluate whether inhibition of 11ß-HSD1 reduced IOP in patients with ocular hypertension (OHT) Methods: Sample size calculations, aiming for a power of 0.9, indicated that 20 patients would be needed to demonstrate a significant drop in IOP following ingestion of CBX at a confidence level of 99%. A randomised, double-blind, placebo-controlled, cross-over trial assessing the effects of oral CBX (100mg three times a day for 4 days) or placebo, on IOP in OHT patients was conducted. Patients with systemic hypertension, underlying endocrine disease and those on exogenous steroids were excluded. IOP readings were taken every 10 minutes for 30 minutes at 5pm on days 1 (Baseline), 5 (Treatment A (CBX or placebo) day 4), 15 (Washout day 10) and 19 (Treatment B day 4) of the study. Blood pressure was measured throughout the study. Statistical analysis was by ANOVA. Results: Following ingestion of CBX there was an overall reduction of IOP by 10% when compared to baseline (p < 0.0001). There was a significant reduction in the IOP in each eye when patients were treated with CBX (right eye p = 0.0003, left eye p = 0.0053) but not when they were taking placebo or during the intermediate washout stage. Blood pressure remained stable throughout the study. Conclusion: These data suggest that 11ß-HSD1 could provide a novel target for treating patients with elevated IOP.

Keywords: 377 corticosteroids • 444 intraocular pressure • 514 pharmacology 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×